Acacia Pharma


€185.5m market cap

€2.12 last close

Acacia Pharma is a commercial-stage biopharmaceutical company developing and commercialising novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy. BARHEMSYS is approved for PONV in the US and in-licensed asset BYFAVO is approved for PS.

Investment summary

Acacia Pharma is focused on bringing antiemetic drugs to the US hospital setting for unmet needs in post-operative nausea and vomiting (PONV) and chemotherapy-induced nausea and vomiting. Its lead product, BARHEMSYS (reformulated amisulpride for the management of PONV), received FDA approval with a broad label in February 2020. Under the deal with Cosmo Pharmaceuticals, Acacia was assigned the US licence for Paion’s sedative BYFAVO (remimazolam), which received FDA approval for procedural sedation (PS) in July 2020. Acacia plans to launch both BARHEMSYS and BYFAVO in H220 and has been building up its US commercial operations in preparation. At 30 June 2020, Acacia had net cash of $21.9m. A share placing in August that raised €25m gross plus access to a €25m loan facility from Cosmo following BYFAVO approval enables Acacia to expand its US commercial infrastructure to support both product launches.

Y/E Dec
Revenue (US$m)
PBT (US$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 0.0 (20.0) (21.6) (45.46) N/A N/A
2019A 0.0 (22.4) (23.5) (37.17) N/A N/A
2020E 2.1 (32.5) (36.2) (40.06) N/A N/A
2021E 28.8 (38.3) (40.0) (46.17) N/A N/A
Industry outlook

Inadequately treated PONV leads to prolonged stays in post-anaesthesia care unit recovery rooms. Use of BARHEMSYS could reduce patient hospitalisation time and the associated costs. Likewise, BYFAVO can reduce the time required for invasive medical procedures, enabling increased patient throughput for hospitals and surgical centres.

Last updated on 21/10/2020
Register to receive research on Acacia Pharma as it is published
Share price graph
Balance sheet
Forecast net cash (US$m) 13.2
Forecast gearing ratio (%) N/A
Price performance
Actual 4.7 (22.6) 41.3
Relative* 5.8 (14.1) 67.1
52-week high/low €3.6/€1.5
*% relative to local index
Key management
Michael Bolinder CEO
Gary Gemignani CFO

Content on Acacia Pharma